Navigation Links
The Michael J. Fox Foundation Leads Charge to Develop Alpha-Synuclein PET Tracer to Image Parkinson's Disease Biomarker

NEW YORK, Nov. 7, 2013 /PRNewswire-USNewswire/ -- The pursuit of an imaging tool to visualize the protein alpha-synuclein, the hallmark pathology of Parkinson's disease (PD), in the brain is the subject of a paper published today in the Journal of Parkinson's Disease by three researchers from The Michael J. Fox Foundation for Parkinson's Research (MJFF). The Foundation has assembled and leads a consortium to develop a radioactive PET tracer that could lead to better therapies and quality of life for Parkinson's patients.

"The time frame for developing a PET tracer can be a long one, on the order of several years, and requires some luck along the way. MJFF seeks to accelerate this process through a concerted effort to combine resources and expertise from several different groups," wrote the paper's authors.

Also today MJFF is hosting a workshop of industry and academic leaders investigating alpha-synuclein and other protein tracers to encourage support and collaboration around this goal.

"The ability to measure biomarkers of Parkinson's disease—including alpha-synuclein in the brain—would radically transform treatments for PD patients by allowing researchers to confirm diagnosis, stratify volunteers for clinical trials and measure drug efficacy faster," said Jamie Eberling, Ph.D., senior associate director of MJFF research programs and first author of the paper. "Availability of an alpha-synuclein tracer would be a huge leap forward for drug development."

Parkinson's disease is marked by clumps of alpha-synuclein, called Lewy bodies, in brain and body cells, which can currently only be measured at autopsy or inferred from protein levels in blood or cerebrospinal fluid. Scientists are hoping to develop a drug with a radioactive tag that can be read by positron emission tomography (PET) scans and that can bind to alpha-synuclein. With this tool, they could visualize the distribution of alpha-synuclein in the brain. Such tracking of these aggregates would help diagnose and track disease progression and monitor therapies targeted at reducing alpha-synuclein levels. As drugs targeting Lewy bodies move through development, researchers could test whether they change levels of alpha-synuclein rather than rely on a change in clinical symptoms, as they do now.

Development of a tracer of the protein beta-amyloid transformed Alzheimer's disease research, leading to insights on how that pathology leads to cognitive decline. PD researchers hope the ability to image alpha-synuclein could allow similar breakthroughs in not only Parkinson's disease, but also related parkinsonisms such as Lewy body dementia, multiple system atrophy and progressive supranuclear palsy.

In 2011 MJFF assembled a consortium with a contract research organization and two academic groups to collaborate on the pursuit of an alpha-synuclein tracer. To identify molecules that bind selectively and with high affinity for the protein, researchers screened 100,000 compounds selected through computational chemistry based on the alpha-synuclein structure. They have identified several promising compounds and continue to optimize them and radiolabel the most promising for further development.

"It is unfortunately a process of trial-and-error. While we're closing in on the compounds with the greatest likelihood of success, there are still hurdles to cross in the next phase of development," said Chester Mathis, Ph.D., director of the PET Facility at the University of Pittsburgh and a member of the MJFF Alpha-Synuclein Imaging Consortium.

The challenges this Parkinson's tracer faces are plenty. Alpha-synuclein is not very abundant in the brain, so the binding compound must be highly selective. Also, it accumulates intracellularly, so in addition to passing the blood-brain barrier, the selected molecule must also make it through the cell membrane. However, advancement to clinical testing of tracers for tau (another protein implicated in Alzheimer's that faces some of these same challenges) provides hope to researchers seeking an alpha-synuclein tracer.

At the workshop today, attendees share best practices and recommendations for next steps as the pursuit continues.

About The Michael J. Fox Foundation for Parkinson's Research

As the world's largest nonprofit funder of Parkinson's research, The Michael J. Fox Foundation is dedicated to accelerating a cure for Parkinson's disease and improved therapies for those living with the condition today. The Foundation pursues its goals through an aggressively funded, highly targeted research program coupled with active global engagement of scientists, Parkinson's patients, business leaders, clinical trial participants, donors and volunteers.  In addition to funding $375 million in research to date, the Foundation has fundamentally altered the trajectory of progress toward a cure. Operating at the hub of worldwide Parkinson's research, the Foundation forges groundbreaking collaborations with industry leaders, academic scientists and government research funders; increases the flow of participants into Parkinson's disease clinical trials with its online tool, Fox Trial Finder; promotes Parkinson's awareness through high-profile advocacy, events and outreach; and coordinates the grassroots involvement of thousands of Team Fox members around the world.

For more information, visit us on Facebook, Twitter, Web and LinkedIn.

SOURCE The Michael J. Fox Foundation for Parkinson's Research
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Dr. Michael Feiz on What Makes a Great Bariatric Physician
2. Michael Walton Retires From The Female Health Company Board of Directors
3. Health Decisions CEO Michael Rosenberg, MD, MPH, Offers Insights into Adaptive and Risk-Based Monitoring in the Journal of Clinical Research Best Practices
4. Red Carpet Star Studded Celebrity Gala in Partnership with the Michael J. Fox Foundation for Parkinsons Research
5. Michael A. Jacobsen Joining Omeros as Vice President, Finance and Chief Accounting Officer
6. Promising Parkinsons Disease Research Highlighted by The Michael J. Fox Foundation to Accelerate Drug Development
7. NeuroDerm Awarded $1M by The Michael J. Fox Foundation for the Clinical Development of ND0612 for Parkinsons Disease
8. Manhattan NYC Cosmetic Dentist Dr. Michael Wei Providing Invisalign Braces
9. American Skin Association Announces New Member Of The Board J. Michael Pearson And New Education Council Member Ryan Weldon Of Valeant Pharmaceuticals International, Inc.
10. Array BioPharma Names Michael N. Needle, M.D. As Chief Medical Officer
11. Chimerix Appoints Michael D. Rogers, Ph.D., as Chief Development Officer
Post Your Comments:
(Date:11/30/2015)... Nov. 30, 2015  Novartis will demonstrate the strength ... th American Society of Hematology (ASH) Annual Meeting. ... as well as supportive care, including key findings in ... cell therapies. The ASH Annual Meeting will be held ... Novartis Oncology . "We will be presenting ...
(Date:11/30/2015)... and BOSTON , November 30, 2015 ... develop potential new medicines directed at up to 10 ... --> PFE ) to research and develop ... protein-coupled receptor (GPCR) targets across multiple therapeutic areas. ... drug discovery and development company and wholly-owned subsidiary of ...
(Date:11/30/2015)... , November 30, 2015 ... or the "Company") announced today that it was informed by ... and Drug Safety (MFDS) has approved its Exablate Neuro ... --> --> Insightec,s Exablate ... treatment alternative that combines two technologies: Focused Ultrasound, which ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... , ... Cycling, running, and walking are regular Sunday activities for many South ... 28, 2016. , That’s when the 7th annual ANF Group Tour de Broward ... and families at Joe DiMaggio Children’s Hospital. , The community fundraiser, sponsored ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... ingredient list of its hemorrhoid ointment to its website. , “Our goal is ... people suffering from hemorrhoids. Adding the comparison chart and ingredient list allows our ...
(Date:11/30/2015)... ... November 30, 2015 , ... At Grand Dental PC, their priority is ... When you have dental problems, you need to turn to a dentist who listens ... treat your needs, a friendly dentist who counsels you on the best ways to ...
(Date:11/30/2015)... ... ... Dr. Seth D. Margulies specializes in orthodontics and is based in Perth ... the best available orthodontic experience in the area. Dr. Margulies has met all ... the branch of dentistry that specializes in the diagnosis, prevention, and treatment of dental ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... new study by UPMC and KingMed Diagnostics researchers. Their ... years found that consultation with UPMC pathologists resulted in significantly altered treatment plans ...
Breaking Medicine News(10 mins):